Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR*EGFR homodimers and EGFR*HER3 heterodimers, thereby blocking downstream pathways. It is applicable for locally advanced or metastatic epithelial tumours, such as non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
Purity:
95.00%
CAS Number:
[2559704-24-2]
Target:
EGFR|||HER
* VAT and and shipping costs not included. Errors and price changes excepted